Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | WNT3A | P56704 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338446 | 1.00 | LMNA (0.67) | LMNAHTTABCC4GAATSHR | |
| SCHEMBL28303354 | 0.85 | MKNK1 (0.62) | LMNAHTTMKNK1MKNK2CYP2A6 | |
| SCHEMBL13492969 | 0.85 | MKNK1 (0.63) | LMNAHTTMKNK1MKNK2CYP2A6 | |
| SCHEMBL2386306 | 0.83 | FFAR1 (0.69) | MKNK1MKNK2CYP2A6FFAR1 | |
| SCHEMBL3941960 | 0.83 | NAPRT (0.67) | NAPRTMKNK1MKNK2CYP2A6KDM4E | |
| SCHEMBL12251218 | 0.82 | MKNK1 (0.58) | LMNAHTTMKNK1MKNK2CYP2A6 | |
| Felbinac SCHEMBL26084 | 0.81 | LMNA (1.00) | LMNAHTTABCC4GAATSHR | |
| SCHEMBL12869883 | 0.81 | KDM4E (0.59) | LMNAHTTMKNK1MKNK2CYP2A6 | |
| SCHEMBL28303343 | 0.81 | MKNK1 (0.57) | LMNAMKNK1MKNK2CYP2A6WNT3A | |
| SCHEMBL5148966 | 0.80 | ABCC4 (0.62) | LMNAHTTABCC4GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501911-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | BNH Research Co., Ltd. (KR) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023191469-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | 주식회사 비엔에이치리서치 | 2023-10-05 | — | — | WO | disclosed |
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | LMNA 1834/4885HTT 1110/4885ABCC4 3758/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | LMNA 4038/4885HTT 1252/4885ABCC4 1299/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | LMNA 394/4885HTT 5/4885ABCC4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.